{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:20:23Z","timestamp":1775082023870,"version":"3.50.1"},"reference-count":25,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Einstein (S\u00e3o Paulo)"],"abstract":"<jats:p>ABSTRACT  Objective  To prospectively compare the results of intradetrusor onabotulinumtoxinA injections and oral oxybutynin for urinary continence, urodynamic parameters and quality of life in patients with neurogenic detrusor overactivity due to spinal cord injury.  Methods  Adult patients under intermittent catheterization were randomized 1:1 to receive one injection of onabotulinumtoxinA 300U or oxybutynin 5mg, per oris, three times\/day. Primary study endpoint was change in urinary incontinence episodes\/24 hours and secondary study endpoints were maximum cystometric capacity, maximum detrusor pressure, bladder compliance and quality of life before randomization and at week 24.  Results  Sixty-eight patients participated in the trial. Significant improvements in urinary incontinence per 24 hours, all investigated urodynamic parameters and quality of life were observed in both groups. Compared with oral oxybutynin, onabotulinumtoxinA was significantly more efficacious for all parameters investigated. Non-response to treatment was higher for oral oxybutynin (23.5%) than onabotulinumtoxinA (11.8%). Dry mouth was the most common adverse in patients with oral oxybutynin (72%) and transient macroscopic hematuria in patients with onabotulinumtoxinA (28%). Only one patient with oral oxybutynin dropped out the study because of adverse effects.  Conclusion  The comparison of the two study drugs showed that onabotulinumtoxinA was significantly more efficacious than oral oxybutynin with regard to continence, urodynamic parameters and quality of life. Clinicaltrials.gov: NCT:01477736.<\/jats:p>","DOI":"10.1590\/s1679-45082018ao4207","type":"journal-article","created":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T15:34:36Z","timestamp":1533396876000},"source":"Crossref","is-referenced-by-count":13,"title":["Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial"],"prefix":"10.1590","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2060-4349","authenticated-orcid":false,"given":"R\u00faiter Silva","family":"Ferreira","sequence":"first","affiliation":[{"name":"Universidade Estadual de Campinas,  Brazil; Centro de Reabilita\u00e7\u00e3o e Readapta\u00e7\u00e3o Dr. Henrique Santillo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5821-0292","authenticated-orcid":false,"given":"Carlos Arturo Levi","family":"D\u2019Ancona","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-2528","authenticated-orcid":false,"given":"Matthias","family":"Oelke","sequence":"additional","affiliation":[{"name":"University of Maastricht,  The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-3269","authenticated-orcid":false,"given":"Maur\u00edcio Rassi","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Centro de Reabilita\u00e7\u00e3o e Readapta\u00e7\u00e3o Dr. Henrique Santillo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2018,8,6]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/j.1464-410X.2009.08600.x","article-title":"Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction","volume":"104","author":"Pannek J","year":"2009","journal-title":"BJU Int"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.eururo.2010.06.035","article-title":"Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses","volume":"58","author":"Grise P","year":"2010","journal-title":"Eur Urol"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","article-title":"Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review","volume":"53","author":"Karsenty G","year":"2008","journal-title":"Eur Urol"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","article-title":"Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial","volume":"184","author":"Abdel-Meguid TA","year":"2010","journal-title":"J Urol"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch B","year":"2005","journal-title":"J Urol"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.eursup.2006.05.006","article-title":"Understanding the role of botulinum toxin A in the treatment of the overactive bladder - more than just muscle relaxation","volume":"5","author":"Apostolidis A","year":"2006","journal-title":"Eur Assoc Urol"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostolidis A","year":"2005","journal-title":"J Urol"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch B","year":"2000","journal-title":"J Urol"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.juro.2009.01.037","article-title":"Cost-effectiveness of botulinum toxin A versus anticholinergic medications for idiopathic urge incontinence","volume":"181","author":"Wu JM","year":"2009","journal-title":"J Urol"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00345-009-0466-1","article-title":"Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany","volume":"28","author":"Wefer B","year":"2010","journal-title":"World J Urol"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.sc.3100432","article-title":"International Standards for Neurological and Functional Classification of Spinal Cord Injury","volume":"35","author":"Maynard Jr FM","year":"1997","journal-title":"Spinal Cord"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11255-008-9402-3","article-title":"Quality of life of neurogenic patients: translation and validation of the Portuguese version of Qualiveen","volume":"41","author":"D\u2019Ancona CA","year":"2009","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/nau.10066","article-title":"Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies","volume":"21","author":"Sch\u00e4fer W","year":"2002","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"61","author":"Abrams P","year":"2003","journal-title":"Urology"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.eururo.2006.03.016","article-title":"Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study","volume":"51","author":"St\u00f6hrer M","year":"2007","journal-title":"Eur Urol"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1464-410X.2003.04468.x","article-title":"Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial","volume":"92","author":"Homma Y","year":"2003","journal-title":"BJU Int"},{"issue":"3","key":"ref17","first-page":"243","article-title":"Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability","volume":"6","author":"Yarker YE","year":"1995","journal-title":"Drugs Aging"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/PL00007103","article-title":"Oxybutynin and the overactive bladder","volume":"19","author":"Andersson KE","year":"2001","journal-title":"World J Urol"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","article-title":"European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity","volume":"45","author":"Reitz A","year":"2004","journal-title":"Eur Urol"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz F","year":"2011","journal-title":"Eur Urol"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg D","year":"2012","journal-title":"J Urol"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2007.04.026","article-title":"Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence","volume":"52","author":"Schurch B","year":"2007","journal-title":"Eur Urol"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.urology.2009.02.047","article-title":"Does optimizing bladder management equal optimizing quality of life? Correlation between health-related quality of life and urodynamic parameters in patients with spinal cord lesions","volume":"74","author":"Pannek J","year":"2009","journal-title":"Urology"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams P","year":"2007","journal-title":"BJU Int"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/jnnp.62.5.473","article-title":"Assessment of autonomic dysreflexia in patients with spinal cord injury","volume":"62","author":"Curt A","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Einstein (S\u00e3o Paulo)"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/eins\/v16n3\/1679-4508-eins-16-03-eAO4207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T15:23:58Z","timestamp":1534346638000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1679-45082018000300202&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,6]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018]]}},"alternative-id":["S1679-45082018000300202"],"URL":"https:\/\/doi.org\/10.1590\/s1679-45082018ao4207","relation":{},"ISSN":["2317-6385","1679-4508"],"issn-type":[{"value":"2317-6385","type":"electronic"},{"value":"1679-4508","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8,6]]}}}